Patents by Inventor Nobuya KOBASHI

Nobuya KOBASHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RI-LABELED HUMANIZED ANTIBODY
    Publication number: 20230094773
    Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Applicants: NIHON MEDI-PHYSICS CO., LTD., SUMITOMO PHARMA CO., LTD.
    Inventors: Norihito Nakata, Nobuya Kobashi, Yoshinari Shoyama, Mitsuhiro Matono, Yasushi Ochiai, Takayuki Murakami
  • Ri-labeled humanized antibody
    Patent number: 11369701
    Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: June 28, 2022
    Assignees: NIHON MEDI-PHYSICS CO., LTD., SUMITOMO PHARMA CO., LTD.
    Inventors: Norihito Nakata, Nobuya Kobashi, Yoshinari Shoyama, Mitsuhiro Matono, Yasushi Ochiai, Takayuki Murakami
  • RI-LABELED HUMANIZED ANTIBODY
    Publication number: 20210338852
    Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Applicants: NIHON MEDI-PHYSICS CO., LTD., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Norihito Nakata, Nobuya Kobashi, Yoshinari Shoyama, Mitsuhiro Matono, Yasushi Ochiai, Takayuki Murakami
  • 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same
    Patent number: 10358434
    Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 23, 2019
    Assignees: NIHON MEDI-PHYSICS CO., LTD., KYOTO UNIVERSITY, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Kei Akama, Yuki Okumura, Yurie Fukui, Nobuya Kobashi, Tsutomu Abe, Yoshihiro Doi, Miho Ikenaga, Hideo Saji, Hiroyuki Kimura, Mitsuhide Naruse
  • 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICAMENT CONTAINING SAME
    Publication number: 20190169169
    Abstract: Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined. Methods for producing various radioactive compounds are also provided.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 6, 2019
    Applicants: NIHON MEDI-PHYSICS CO., LTD., Kyoto University, National Hospital Organization
    Inventors: Akihiro IZAWA, Kei AKAMA, Yuki OKUMURA, Yurie FUKUI, Nobuya KOBASHI, Tsutomu ABE, Yoshihiro DOI, Miho IKENAGA, Hideo SAJI, Hiroyuki KIMURA, Mitsuhide NARUSE
  • 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same
    Patent number: 10189815
    Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: January 29, 2019
    Assignees: NIHON MEDI-PHYSICS CO., LTD., KYOTO UNIVERSITY, NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Kei Akama, Yuki Okumura, Yurie Fukui, Nobuya Kobashi, Tsutomu Abe, Yoshihiro Doi, Miho Ikenaga, Hideo Saji, Hiroyuki Kimura, Mitsuhide Naruse
  • 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME
    Publication number: 20170158668
    Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.
    Type: Application
    Filed: June 25, 2015
    Publication date: June 8, 2017
    Applicants: Nihon Medi-Physics Co., Ltd., Kyoto University, National Hospital Organization
    Inventors: Akihiro IZAWA, Kei AKAMA, Yuki OKUMURA, Yurie FUKUI, Nobuya KOBASHI, Tsutomu ABE, Yoshihiro DOI, Miho IKENAGA, Hideo SAJI, Hiroyuki KIMURA, Mitsuhide NARUSE